AM22-13-O: (On-Demand) Effects of Transfusion on Bone Marrow Health and Transplant Outcomes in Sickle Cell Disease (Enduring)
AM22-13-O: (On-Demand) Effects of Transfusion on Bone Marrow Health and Transplant Outcomes in Sickle Cell Disease (Enduring) is organized by Association for the Advancement of Blood & Biotherapies (AABB).
Expiration Date: Dec 31, 2024
Description:
Bone marrow pathology in SCD, such as decreased mesenchymal stem cell function and disordered vasculature, has recently been described in pre-clinical models and has been shown to be responsive to red cell transfusion. A speaker will review her and others’ research in this area and its implications for peri-transplant transfusion support. Another speaker will discuss the association of HLA and red cell alloantibodies with important allogeneic transplant outcomes in SCD such as graft versus host disease, donor T cell chimerism, and even overall survival. Both speakers will speak to the implication of these findings for best practice transfusion support for SCD patients pre- and peri-transplant.
All relevant financial relationships have been mitigated.
Learning Objectives:
• Describe the potential of transfusion to improve allogeneic transplant and gene therapy outcomes in SCD through its effects on the bone marrow microenvironment.
• Describe the association of HLA and red cell alloantibodies with allogeneic transplant outcomes in SCD.
• Discuss best practice of transfusion support for SCD patients pre- and peri-transplant in the autologous and allogeneic setting.
Additional details will be posted as soon as information is available.